Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL947966

CCCCOc1cccc(CCNCCC(=O)O)c1.O=C(O)C(F)(F)F

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 9/20 0.60
KCNH2 Q12809 7/20 0.59
LTA4H P09960 1/20 0.53
S1PR1 P21453 3/20 0.52
S1PR3 Q99500 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL948321 0.97 CYP2D6 (0.61) CYP2D6KCNH2S1PR1
Trifluoroacetic Acid SCHEMBL947011 0.96 CYP2D6 (0.61) CYP2D6KCNH2S1PR1S1PR3
Trifluoroacetic Acid SCHEMBL946343 0.96 CYP2D6 (0.61) CYP2D6KCNH2S1PR1S1PR3
Trifluoroacetic Acid SCHEMBL948823 0.96 CYP2D6 (0.61) CYP2D6KCNH2S1PR1S1PR3
Trifluoroacetic Acid SCHEMBL949915 0.96 CYP2D6 (0.61) CYP2D6KCNH2S1PR1S1PR3
Trifluoroacetic Acid SCHEMBL947789 0.96 CYP2D6 (0.61) CYP2D6KCNH2S1PR1S1PR3
Trifluoroacetic Acid SCHEMBL947998 0.95 S1PR1 (0.60) CYP2D6KCNH2LTA4HS1PR1S1PR3
SCHEMBL3200254 0.93 CYP2D6 (0.67) CYP2D6KCNH2LTA4HS1PR1S1PR3
Trifluoroacetic Acid SCHEMBL949642 0.92 S1PR1 (0.57) CYP2D6KCNH2LTA4HS1PR1S1PR3
Trifluoroacetic Acid SCHEMBL947310 0.91 S1PR1 (0.58) CYP2D6KCNH2LTA4HS1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2883865-A1 Compound capable of binding S1P receptor and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2015-06-17 EP disclosed
US-20140288034-A1 COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2014-09-25 US disclosed
US-8791159-B2 Compound capable of binding S1P receptor and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-07-29 US disclosed
US-20110020324-A1 COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD (JP) 2011-01-27 US disclosed
US-7825109-B2 Compound capable of binding S1P receptor and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-11-02 US disclosed
CN-101407471-A Compound capable of binding S1P receptor and pharmaceutical use thereof ONO PHARMACEUTICAL CO (JP) 2009-04-15 CN disclosed
US-20070167425-A1 Compound capable of binding s1p receptor and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD (JP) 2007-07-19 US disclosed
EP-1661881-A2 COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288034-A1 COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF S1PR1, S1PR2, S1PR3 CYP2D6 1819/4885KCNH2 1238/4885LTA4H 427/4885
US-20070167425-A1 Compound capable of binding s1p receptor and pharmaceutical use thereof S1PR1, S1PR3, S1PR2 CYP2D6 594/4885KCNH2 1903/4885LTA4H 697/4885
US-20110020324-A1 COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF S1PR1, S1PR3, S1PR2 CYP2D6 594/4885KCNH2 1903/4885LTA4H 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.